MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III study

AIM: To compare the efficacy, safety, and tolerability of abemaciclib plus endocrine therapy (ET) versus ET alone in postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) from China, Brazil, India, and South Af...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Adv Med Oncol
Main Authors: Zhang, Qing Yuan, Sun, Tao, Yin, Yong Mei, Li, Hui Ping, Yan, Min, Tong, Zhong Sheng, Oppermann, Christina P., Liu, Yun Peng, Costa, Romulo, Li, Man, Cheng, Ying, Ouyang, Qu Chang, Chen, Xi, Liao, Ning, Wu, Xin Hong, Wang, Xiao Jia, Feng, Ji Feng, Hegg, Roberto, Kanakasetty, G.B., Coccia-Portugal, Maria A., Han, Ru Bing, Lu, Yi, Chi, Hai Dong, Jiang, Ze Fei, Hu, Xi Chun
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7586037/
https://ncbi.nlm.nih.gov/pubmed/33149768
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920963925
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados